| Type of support |
Approvals 2001-2023 (US$)(17 Sep 2019) |
Commitments 2001-2023 (US$)(17 Sep 2019) |
Disbursements 2000-2019 (US$)(17 Sep 2019) |
% Disbursed(17 Sep 2019) |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
|---|
|
| Total |
$967,796,630 |
$1,096,366,271 |
$894,611,352 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Civil Society Organisation support (CSO) |
$9,757,132 |
$9,757,132 |
$9,857,132 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cold Chain Equipment Optimisation Platform (CCEOP) |
$22,379,004 |
$22,379,004 |
$21,105,063 |
94% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ebola EPI Recovery Plan (EEPIRP) |
$9,204,421 |
$9,204,421 |
$9,204,421 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$55,759,817 |
$55,759,817 |
$55,759,817 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 2) |
$148,852,874 |
$148,852,874 |
$135,429,327 |
91% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$25,807,280 |
$25,807,280 |
$25,807,280 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$6,089,473 |
$9,786,473 |
$5,903,801 |
97% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$2,713,931 |
$2,713,931 |
$2,713,931 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$19,787,846 |
$19,787,846 |
$21,146,157 |
107% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles SIA (NVS) |
$11,710,012 |
$11,710,012 |
$11,710,012 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles SIA - Operational costs (OPC) |
$19,805,713 |
$19,805,713 |
$19,805,713 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Follow-up campaign (NVS) |
$6,762,500 |
$6,762,500 |
$6,811,686 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Follow-up campaign op.costs (OPC) |
$12,222,101 |
$12,222,101 |
$4,888,840 |
40% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - campaign (NVS) |
$13,744,023 |
$13,744,023 |
$13,744,023 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - operational costs (OPC) |
$11,645,500 |
$11,645,500 |
$11,645,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$176,031,505 |
$176,031,505 |
$178,452,315 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$279,581,988 |
$279,581,988 |
$298,735,691 |
107% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Product Switch Grant (PSG) |
$823,513 |
$823,513 |
$823,513 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$20,449,000 |
$20,449,000 |
$2,028,844 |
10% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tetra DTP-HepB (NVS) |
$10,357,601 |
$10,357,601 |
$10,357,601 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$8,051,003 |
$8,051,003 |
$6,592,615 |
82% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Yellow Fever (NVS) |
$40,928,736 |
$40,928,736 |
$42,088,070 |
103% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Yellow Fever - campaign (NVS) |
$34,794,500 |
$124,778,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YF - Operational costs (OPC) |
$20,537,157 |
$55,425,797 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format